{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:49:31Z","timestamp":1772189371891,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82161138021"],"award-info":[{"award-number":["82161138021"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202006240091"],"award-info":[{"award-number":["202006240091"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["468853597"],"award-info":[{"award-number":["468853597"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.euroneuro.2024.04.007","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T04:48:37Z","timestamp":1713674917000},"page":"21-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Single-arm meta-analysis of drug response in placebo-controlled versus active-controlled antipsychotic drug trials in schizophrenia"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8095-0545","authenticated-orcid":false,"given":"Shimeng","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Schneider-Thoma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-2039","authenticated-orcid":false,"given":"Spyridon","family":"Siafis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5058-3270","authenticated-orcid":false,"given":"Natalie","family":"Peter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2024.04.007_bib0001","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1176\/appi.ajp.2013.12030315","article-title":"Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010","volume":"170","author":"Agid","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0002","doi-asserted-by":"crossref","first-page":"e9479","DOI":"10.1371\/journal.pone.0009479","article-title":"Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology","volume":"5","author":"Brunoni","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0003","series-title":"Application Number: 200603: Summary Review","year":"2010"},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0004","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/archpsyc.1964.01720210028005","article-title":"Phenothiazine Treatment in Acute Schizophrenia","volume":"10","author":"Cole","year":"1964","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0005","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archpsyc.60.5.458","article-title":"Placebo or active control trials of antipsychotic drugs?","volume":"60","author":"Fleischhacker","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0007","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0008","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3","author":"Higgins","year":"2022"},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0009","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.euroneuro.2022.06.003","article-title":"Is superiority to placebo the most appropriate measure of efficacy in trials of novel psychotropic medications?","volume":"62","author":"Huneke","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0011","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1001\/archpsyc.62.12.1305","article-title":"Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis","volume":"62","author":"Kemmler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0012","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.schres.2018.05.009","article-title":"60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: meta-regression of predictors of placebo response","volume":"201","author":"Leucht","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0013","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1038\/s41386-019-0440-6","article-title":"Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis","volume":"44","author":"Leucht","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0014","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia","volume":"177","author":"Leucht","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0015","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0016","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.schres.2022.01.001","article-title":"About the issue of including or excluding studies from China in systematic reviews","volume":"240","author":"Leucht","year":"2022","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0017","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.euroneuro.2012.11.004","article-title":"Equipercentile linking of the BPRS and the PANSS","volume":"23","author":"Leucht","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2024.04.007_bib0018","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: the DDD method","volume":"42","author":"Leucht","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0019","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/schbul\/sbv037","article-title":"Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method","volume":"41","author":"Leucht","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0020","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/schbul\/sbu001","article-title":"Dose equivalents for second-generation antipsychotics: the minimum effective dose method","volume":"40","author":"Leucht","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0021","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/wps.21089","article-title":"Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis","volume":"22","author":"Leucht","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0022","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/wps.20977","article-title":"Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta-analysis","volume":"21","author":"McCutcheon","year":"2022","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0023","series-title":"R: A Language and Environment for Statistical Computing","author":"Core Team","year":"2022"},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0024","series-title":"Experimenter Effects in Behavioral Research","author":"Rosenthal","year":"1976"},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0025","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamapsychiatry.2014.1319","article-title":"Placebo response in antipsychotic clinical trials: a meta-analysis","volume":"71","author":"Rutherford","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0026","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"152","author":"Schulz","year":"2010","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0027","series-title":"meta: An R Package for Meta-Analysis","first-page":"40","author":"Schwarzer","year":"2007"},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0028","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.euroneuro.2022.05.002","article-title":"Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs","volume":"60","author":"Similon","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.04.007_bib0029","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12874-018-0554-2","article-title":"Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Med. Res. Methodol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X24000920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X24000920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T11:20:00Z","timestamp":1719832800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X24000920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":29,"alternative-id":["S0924977X24000920"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2024.04.007","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-arm meta-analysis of drug response in placebo-controlled versus active-controlled antipsychotic drug trials in schizophrenia","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2024.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}